SunTrust Robinson Humphrey Initiates Coverage On PTC Therapeutics with Buy Rating, Announces $78 Price Target

SunTrust Robinson Humphrey initiates coverage on PTC Therapeutics (NASDAQ:PTCT) with a Buy rating and a $78 price target.

Benzinga · 11/12/2019 11:31

SunTrust Robinson Humphrey initiates coverage on PTC Therapeutics (NASDAQ:PTCT) with a Buy rating and a $78 price target.